D2 Thr92Ala and PPARγ2 pro12ala polymorphisms interact in the modulation of insulin resistance in type 2 diabetic patients

Obesity

Volumn 19, Issue 4, 2011, Pages 825-832

  Estivalet, Aline A F ^a   Leiria, Leonardo B ^a   Dora, José M ^a   Rheinheimer, Jakeline ^a   Bouças, Ana P ^a   Maia, Ana L ^a   Crispim, Daisy ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA2 GENE; TYPE 2 DEIODINASE GENE;

AGED; ALLELES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 79953192130     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.231     Document Type: Article

References (37)

1. American DA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32 (Suppl 1):S62-S67.
2. Fröjdö S, Vidal H, Pirola L Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim Biophys Acta 2009;1792:83-92
3. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38-89. (Pubitemid 34185306)
4. Croteau W, Davey JC, Galton VA, St Germain DL Cloning of the mammalian type II iodothyronine deiodinase. A selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J Clin Invest 1996;98:405-417. (Pubitemid 26255740)
5. Salvatore D, Bartha T, Harney JW, Larsen PR. Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 1996;137:3308-3315. (Pubitemid 26250180)
6. Weinstein SP, O'Boyle E, Haber RS. Thyroid hormone increases basal and insulin-stimulated glucose transport in skeletal muscle. The role of GLUT4 glucose transporter expression. Diabetes 1994;43:1185-1189 (Pubitemid 24361182)
7. Torrance CJ, Devente JE, Jones JP Dohm GL. Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. Endocrinology 1997;138:1204-1214. (Pubitemid 27089779)
8. Richardson JM, Pessin JE. Identification of a skeletal muscle-specific regulatory domain in the rat GLUT4/muscle-fat gene. J Biol Chem 1993;268:21021-21027. (Pubitemid 23292285)
9. Mentuccia D, Proietti-Pannunzi L, Tanner K et al. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor Diabetes 2002;51:880-883 (Pubitemid 34760206)
10. Canani LH, Capp C, Dora JM et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2005;90:3472-3478. (Pubitemid 41014316)
11. Grarup N, Andersen MK, Andreasen CH et al. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab 2007;92:363-366. (Pubitemid 46067554)
12. Maia AL, Dupuis J, Manning A et al. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study Thyroid 2007;17:199-202. (Pubitemid 46557366)
13. Mentuccia D, Thomas MJ, Coppotelli G et al. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid 2005;15:1223-1227. (Pubitemid 41821754)
14. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
15. Deeb SS, Fajas L, Nemoto M et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity lower body mass index and improved insulin sensitivity Nat Genet 1998;20:284-287. (Pubitemid 28507675)
16. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002;51:2341-2347. (Pubitemid 34827380)
17. Fiorito M, Torrente I, De Cosmo S et al. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome. Obesity (Silver Spring) 2007;15:2889-2895 (Pubitemid 351256647)
18. Canani LH, Capp C, Ng DP et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 2005;54:3326-3330. (Pubitemid 43334390)
19. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity Diabetes Care 2000;23:57-63 (Pubitemid 30022895)
20. Seligman BG, Biolo A, Polanczyk CA, Gross JL, Clausell N. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2000;23:1395-1400.
21. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:193-205 (Pubitemid 351301824)
22. Weinstein SP, O'Boyle E, Fisher M, Haber RS. Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. Endocrinology 1994;135:649-654. (Pubitemid 24241246)
23. Peeters RP, van Toor H, Klootwijk W et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003;88:2880-2888. (Pubitemid 36724470)
24. Meulenbelt I, Min JL, Bos S et al. Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis. Hum Mol Genet 2008;17:1867-1875 (Pubitemid 351791514)
25. Guo TW, Zhang FC, Yang MS et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. J Med Genet 2004;41:585-590.
26. Chistiakov DA, Savost'anov KV Turakulov RI. Screening of SNPs at 18 positional candidate genes, located within the GD-1 locus on chromosome 14q23-q32, for susceptibility to Graves' disease: a TDT study Mol Genet Metab 2004;83:264-270. (Pubitemid 39473069)
27. Gumieniak O, Perlstein TS, Williams JS et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007;49:461-466.
28. Stolerman ES, Florez JC Genomics of type 2 diabetes mellitus: implications for the clinician. Nat Rev Endocrinol 2009;5:429-436.
29. Lin Y Sun Z. Current views on type 2 diabetes. J Endocrinol 2010;204:1-11
30. Ahmed W, Ziouzenkova O, Brown J et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007;262:184-198. (Pubitemid 47087629)
31. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182. (Pubitemid 36177070)
32. Tönjes A, Stumvoll M. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk. Curr Opin Clin Nutr Metab Care 2007;10:410-414 (Pubitemid 46934108)
33. Tönjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006;29:2489-2497 (Pubitemid 44912258)
34. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007;92:386-395
35. Grozovsky R, Ribich S, Rosene ML et al. Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology 2009;150:1976-1983.
36. Emoto M, Nishizawa Y Maekawa K et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999;22:818-822. (Pubitemid 29220786)
37. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495 (Pubitemid 38680001)